Third Harmonic Bio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Out of Business

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Out of Business

Third Harmonic Bio General Information

Description

Developer of an oral KIT inhibitor designed for the treatment of severe allergy and inflammation. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate, THB335, is a potent, selective, oral small molecule KIT inhibitor for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 300 Technology Square
  • 8th Floor
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 300 Technology Square
  • 8th Floor
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Third Harmonic Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 30-Jan-2026 Completed Out of Business
4. IPO 14-Sep-2022 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 16-Feb-2022 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 01-Nov-2021 $50M $50M Completed Startup
1. Seed Round 01-Jan-2019 Completed Startup
To view Third Harmonic Bio’s complete valuation and funding history, request access »

Third Harmonic Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-3
Series A-2 13,750,000 $0.000100 8% $1.6 $1.6 1x $1.6 20.29%
Series A-1 19,970,000 $0.000100 8% $1 $1 1x $1 29.47%
To view Third Harmonic Bio’s complete cap table history, request access »

Third Harmonic Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an oral KIT inhibitor designed for the treatment of severe allergy and inflammation. The company's product
Discovery Tools (Healthcare)
Cambridge, MA
31 As of 2025

Minneapolis, MN
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Third Harmonic Bio Competitors (5)

One of Third Harmonic Bio’s 5 competitors is Celcuity, a Formerly VC-backed company based in Minneapolis, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Celcuity Formerly VC-backed Minneapolis, MN
Immunomic Therapeutics Venture Capital-Backed Rockville, MD
Forte Biosciences Formerly PE-Backed Dallas, TX
BioVie Formerly VC-backed Carson City, NV
Cellectis Formerly VC-backed Paris, France
You’re viewing 5 of 5 competitors. Get the full list »

Third Harmonic Bio Patents

Third Harmonic Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025259929-A1 Compounds and compositions as c-kit kinase inhibitors Pending 13-Jun-2024
WO-2025256609-A1 Crystalline forms of a selective c-kit kinase inhibitor Pending 13-Jun-2024
WO-2024123966-A1 Compounds and compositions as c-kit kinase inhibitors Inactive 07-Dec-2022
WO-2024124002-A1 Compounds and compositions as c-kit kinase inhibitors Inactive 07-Dec-2022
WO-2022182982-A1 Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor Inactive 26-Feb-2021 A61K31/437
To view Third Harmonic Bio’s complete patent history, request access »

Third Harmonic Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Third Harmonic Bio ESG

Risk Overview

Risk Rating

Updated September, 30, 2023

34.1 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 435

Rank

Percentile

To view Third Harmonic Bio’s complete esg history, request access »

Third Harmonic Bio FAQs

  • When was Third Harmonic Bio founded?

    Third Harmonic Bio was founded in 2019.

  • Where is Third Harmonic Bio headquartered?

    Third Harmonic Bio is headquartered in Cambridge, MA.

  • What is the size of Third Harmonic Bio?

    Third Harmonic Bio has 31 total employees.

  • What industry is Third Harmonic Bio in?

    Third Harmonic Bio’s primary industry is Discovery Tools (Healthcare).

  • Is Third Harmonic Bio a private or public company?

    Third Harmonic Bio is a Private company.

  • What is Third Harmonic Bio’s current revenue?

    The current revenue for Third Harmonic Bio is .

  • How much funding has Third Harmonic Bio raised over time?

    Third Harmonic Bio has raised $340M.

  • Who are Third Harmonic Bio’s competitors?

    Celcuity, Immunomic Therapeutics, Forte Biosciences, BioVie, and Cellectis are competitors of Third Harmonic Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process